ClinicalTrials.gg
RecruitingNCT07743164Updated Nov 17, 2026

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

A Phase 3 interventional study of R-DXd and Bevacizumab in Ovarian Cancer, Peritoneal Cancer and Fallopian Tube Cancer, sponsored by Merck Sharp & Dohme LLC. Recruiting at 9 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 17, 2026Now RecruitingFirst sites in 5 new countries+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
646
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Ovarian Neoplasms by Merck & Co., Inc — 6 open to participants now, 7 under way, 5 of them phase 3. Ovarian Neoplasms · Merck & Co., Inc.

Planned enrollment
5th of 25
646 · median 132
Started
2026
with 3 others
Phase 3
6 of 27
4 open now
Registered
25th of 27
by date

Among the 27 studies in Ovarian Neoplasms by Merck & Co., Inc, this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 in phase 3, and was the 25th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 27 studies in Ovarian Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Ovarian Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells grow and spread quickly. This trial includes types of OC that started in cells that cover the ovaries, in the lining of the belly, or in the fallopian tubes.

The usual treatment for high-grade OC may include one or both of these:

  • Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing.
  • Bevacizumab, which is a targeted therapy that works to control how specific types of cancer cells grow and spread and targets tumor blood vessels.

Researchers want to learn about the trial medicine, raludotatug deruxtecan (also called R-DXd or MK-5909), when given with and without bevacizumab and how participants respond to it. R-DXd is an antibody drug conjugate (ADC). An ADC is a type of medicine that attaches to a specific target on cancer cells and delivers treatment to destroy those cells.

The goals of this trial are to learn if participants who receive R-DXd, with or without bevacizumab, live longer overall and without their cancer growing or spreading compared to those who receive usual treatment.

03

Conditions studied

  • Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

The main inclusion criteria include but are not limited to the following:

  • Has a or cytologically documented advanced high-grade serous or high-grade endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer.
  • Has received 1 line of platinum-based therapy with a minimum of 4 cycles of platinum-doublet chemotherapy and have platinum-sensitive disease.
  • Has received a poly (ADP-ribose) polymerase inhibitor (PARPi) as maintenance treatment after the platinum-based chemotherapy course and experienced radiographic progression during treatment or within 42 days of the last dose of PARPi.
  • Has an (ECOG) performance status of 0 or 1 assessed within 7 days before randomization.
  • Has recovered from any AEs due to previous anticancer therapies.

The main exclusion criteria include but are not limited to the following:

  • Has clear cell, mucinous, or sarcomatous histology, mixed tumors containing any histology, or low-grade/borderline ovarian cancer.
  • Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active GI bleeding within 6 months before randomization.
  • Has uncontrolled or significant cardiovascular disease.
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of randomization, severe asthma, severe [COPD], restrictive lung disease, pleural effusion) and any , connective tissue, or inflammatory disorders with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis), or prior pneumonectomy.
  • Has received chronic treatment, with some exceptions.
  • Has current, bowel obstruction (including subocclusive disease) including obstruction related to underlying epithelial ovarian cancer, abdominal fistula or GI perforation, intra-abdominal abscess, or evidence of rectosigmoid involvement by pelvic exam.
  • Has known additional that is progressing or has required active treatment within the past 3 years.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
646 participants (estimated)

Study arms

  • Experimental
    R-DXd +/- Bevacizumab

    Participants will receive intravenous (IV) raludotatug deruxtecan (R-DXd) with or without IV bevacizumab for up to 2 years until progressive disease (PD), unacceptable toxicity, or other protocol-specified reason for discontinuation

    Biological: R-DXd · Drug: Bevacizumab

  • Active comparator
    Standard of Care

    Participants receive 6 to 8 cycles of investigator's choice of one of three options of platinum-based chemotherapy with or without IV bevacizumab. Bevacizumab treatment if elected, will continue until PD, unacceptable toxicity, or other protocol specified reason for discontinuation

    Drug: Bevacizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Gemcitabine · Drug: Pegylated liposomal doxorubicin (PLD)

Interventions

  • BiologicalR-DXd

    R-DXd alone or in combination with bevacizumab administered via IV infusion

    Also known as: raludotatug deruxtecan, MK-5909, DS-6000a

  • Bevacizumab 10 or 15 mg/kg administered via IV infusion on day 1 q3w

    Also known as: AVASTIN®, MVASI®

  • Carboplatin area under the curve (AUC) 5 mg/mL\*min or AUC 4 mg/mL\*min administered on day 1 q3w for a maximum of 8 cycles

  • Paclitaxel 175 mg/m\^2 administered via IV infusion on day 1 q3w for a maximum of 8 cycles

  • Gemcitabine 1000 mg/mL administered via IV infusion on day 1 and day 8 of each 3-week cycle for a maximum of 8 cycles

  • PLD 30 mg/m\^2 administered via IV infusion on day 1 of each 4-week cycles for a maximum of 8 cycles

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time from randomization to the first documented disease progression per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause, whichever occurs first. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered disease progression. PFS as assessed by blinded independent central review (BICR) will be presented.

    Time frame: Up to approximately 3 years

  2. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Number of Participants who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 3 years

  2. Number of Participants who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 3 years

  3. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to approximately 3 years

  4. Duration of Response (DOR)

    For participants who demonstrate confirmed CR or PR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Per RECIST 1.1, disease progression (DP) is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered DP.

    Time frame: Up to approximately 3 years

  5. Progression-free Survival 2 (PFS2)

    PFS2 is defined as the time from randomization to the documented subsequent objective disease progression after initiation of new anticancer therapy or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 4 years

  6. Time to First Subsequent Anticancer Treatment (TFST)

    TFST is defined as the time from randomization to initiation of first subsequent anticancer treatment or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 3 years

  7. Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire 30- (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score

    EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.

    Time frame: Baseline and at designated time points up to approximately 3 years

  8. Change from Baseline in EORTC Quality of Life Questionnaire Ovarian Cancer Module 28 (QLQ-OV28) Abdominal/Gastrointestinal (GI) Scale

    EORTC QLQ-OV28 is an ovarian cancer-specific module to supplement the EORTC QLQ-C30. Participant responses to the 6 abdominal/GI symptoms scale questions are scored on a 4-point scale (1=not at all, 4=very much). The combined score is computed by averaging the raw scores of the 6 items and then applying a linear transformation to standardize the average score, so that the combined score ranges from 0 to 100. The change from baseline in abdominal and gastrointestinal symptoms (EORTC QLQ-OC28 Items 31-36) score will be presented. A lower score indicates a better outcome.

    Time frame: Baseline and at designated time points up to approximately 3 years

07

Study locations

9 of 9 sites recruiting
  • MemorialCare Orange Coast Medical Center ( Site 0032)
    Fountain Valley, California 92708, United States
    Recruiting
    • Study Coordinator · Contact562-972-8625
  • Orlando Health Cancer Institute ( Site 0018)
    Orlando, Florida 32806, United States
    Recruiting
    • Study Coordinator · Contact321-841-1869
  • Lahey Clinic ( Site 0042)
    Burlington, Massachusetts 01805, United States
    Recruiting
    • Study Coordinator · Contact781-744-3421
  • JPS Oncology and Infusion Center ( Site 0019)
    Fort Worth, Texas 76104, United States
    Recruiting
    • Study Coordinator · Contact817-702-7001
  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology ( Site 9000)
    Wuhan, Hubei 430030, China
    Recruiting
    • Study Coordinator · Contact+8602783662688
  • Hadassah Medical Center ( Site 2700)
    Jerusalem, 9112001, Israel
    Recruiting
    • Study Coordinator · Contact+97226777333
  • Sourasky Medical Center ( Site 2701)
    Tel Aviv, 6423906, Israel
    Recruiting
    • Study Coordinator · Contact+97236974444
  • Seoul National University Hospital ( Site 5202)
    Seoul, 03080, South Korea
    Recruiting
    • Study Coordinator · Contact+82220724863
  • National Cheng Kung University Hospital ( Site 5304)
    Tainan, 704302, Taiwan
    Recruiting
    • Study Coordinator · Contact+88662353535
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Aug 2031, 58 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 58 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 3, 2026
StartActual
Oct 7, 2026
Primary completionEst.
Aug 31, 2031
CompletionEst.
Aug 31, 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
9 sites added — first sites in Israel, Taiwan, United States, China and South Korea. Sourasky Medical Center ( Site 2701) is now Recruiting
Show 9 added (4 United States, 2 Israel, 1 Taiwan, 1 China, 1 South Korea)
  • Sourasky Medical Center ( Site 2701) · Tel Aviv, Israel
  • MemorialCare Orange Coast Medical Center ( Site 0032) · Fountain Valley, United States
  • Orlando Health Cancer Institute ( Site 0018) · Orlando, United States
  • National Cheng Kung University Hospital ( Site 5304) · Tainan, Taiwan
  • JPS Oncology and Infusion Center ( Site 0019) · Fort Worth, United States
  • Hadassah Medical Center ( Site 2700) · Jerusalem, Israel
  • Lahey Clinic ( Site 0042) · Burlington, United States
  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology ( Site 9000) · Wuhan, China
  • Seoul National University Hospital ( Site 5202) · Seoul, South Korea
across 5 updates, Oct 2, 2026 – Nov 17, 2026
Start date
Oct 5, 2026→Oct 7, 2026 (actual)
Oct 16, 2026
Show all 5 updates
  1. Nov 17, 2026
    2 sites added — first sites in China and South Korea
    Show 2 added (1 China, 1 South Korea)
    • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology ( Site 9000) · Wuhan, China
    • Seoul National University Hospital ( Site 5202) · Seoul, South Korea
  2. Nov 10, 2026
    1 site added
    Show site
    • Lahey Clinic ( Site 0042) · Burlington, United States
    + 1 other change: verification date
  3. Oct 30, 2026
    2 sites added
    Show 2 added (1 United States, 1 Israel)
    • JPS Oncology and Infusion Center ( Site 0019) · Fort Worth, United States
    • Hadassah Medical Center ( Site 2700) · Jerusalem, Israel
    + 1 other change: references
  4. Oct 16, 2026
    Not yet recruiting→Recruiting
    3 sites added — first sites in Taiwan and United States. Sourasky Medical Center ( Site 2701) is now Recruiting
    Show 3 added (2 United States, 1 Taiwan)
    • MemorialCare Orange Coast Medical Center ( Site 0032) · Fountain Valley, United States
    • Orlando Health Cancer Institute ( Site 0018) · Orlando, United States
    • National Cheng Kung University Hospital ( Site 5304) · Tainan, Taiwan
    Start date Oct 5, 2026→Oct 7, 2026 (now actual)
    + 1 other change: verification date
  5. Oct 2, 2026
    1 site added — first site in Israel
    Show site
    • Sourasky Medical Center ( Site 2701) · Tel Aviv, Israel

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07743164
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Oct 7, 2026
Primary completion
Aug 31, 2031 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Raludotatug deruxtecan

Start the discussion